文献速递头颈外科

联合检测EFS、GPX2和SPRR1A表达可区分上皮样头颈癌亚型中的良好与不良临床结局

The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes.
PubMed 文献 · Head Neck · 2019-01-16

研究基于上皮样(EL)与间质样(ML)细胞表型差异,建立三基因(EFS、GPX2、SPRR1A)生存模型,利用TCGA-HNSC的RNA-seq数据构建,并在两个独立队列中验证其预后价值。EL细胞对顺铂和西妥昔单抗敏感、迁移低,并在小鼠中生成鳞状分化肿瘤。EFS、GPX2和SPRR1A是可区分EL表型亚型临床结局的预后标志物。

要点

  • EL细胞对顺铂和西妥昔单抗敏感,迁移能力低,在小鼠中生成鳞状分化肿瘤。
  • 基于ML与EL细胞间93基因表达特征,用TCGA-HNSC的RNA-seq数据构建三基因(EFS、GPX2、SPRR1A)生存模型。
  • 该三基因模型的预后价值在两个独立队列中得到验证。

核心结论

  • EFS、GPX2和SPRR1A是可区分共享上皮样表型亚型临床结局的预后标志物。

研究设计与样本

  • 研究分析EL与ML细胞与迁移、耐药或肿瘤生长的关联,并基于细胞类型间差异基因表达谱构建按生存分层的模型。
  • 利用TCGA-HNSC项目的RNA-seq数据,以ML与EL细胞间93基因表达特征构建三基因(EFS、GPX2、SPRR1A)生存模型,并在两个独立队列中验证其预后价值。

主要发现

  • EL细胞对顺铂和西妥昔单抗敏感,迁移能力低,并在小鼠中生成鳞状分化肿瘤。
  • ML与EL细胞间存在93基因差异表达特征。
  • 三基因(EFS、GPX2、SPRR1A)生存模型的预后价值在两个独立队列中得到确认。

关键数值与推荐

  • 三基因模型由EFS、GPX2和SPRR1A组成,基于TCGA-HNSC的RNA-seq数据构建。
  • ML与EL细胞间差异表达特征包含93个基因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial-like (EL) or mesenchymal-like (ML) phenotypes. MATERIALS AND METHODS: We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival. RESULTS: EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93-gene expression signature between ML and EL cells was used to build a three-gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA-seq data of the TCGA-HNSC project. Its prognostic value was confirmed in two independent cohorts. CONCLUSION: EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Pavón MA, Arroyo-Solera I, León X, et al. The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes. Head Neck. 2019. PMID: 30652380. doi:10.1002/hed.25623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。